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1. Introduction    
The systemic endemic mycoses are a group of microbial pathologies affecting primarily the 
lower respiratory tract, often overlooked in the evaluation of community-acquired 
pneumonia. They form a heterogeneous group caused by dimorphic fungi that share similar 
characteristics. All of them have the respiratory tract as the portal of entry and from the 
lungs they may disseminate to the mucous membranes, the skin, and many other organs. 
Nonetheless, each fungal disease has specific characteristics concerning its clinical course, 
diagnosis, and management. Interestingly, specific geographical areas of the world have 
been associated with acquisition of these mycoses. The diagnosis may be difficult and 
delayed owing to the varied manifestations and the multitude of differential diagnoses 
(Bonifaz et al., 2011; Hsu et al., 2010).  
The major endemic systemic mycoses include histoplasmosis, coccidioidomycosis, 
blastomycosis, paracoccidioidomycosis (PCM), and penicilliosis. All of them can cause 
disease in both immunocompetent and immunocompromised hosts, in particular, AIDS and 
organ transplantation patients, and more recently recipients of biological therapies, such as 
TNF inhibitors or antagonists. These mycoses have similar clinical and radiologic 
presentations but require different treatments. Furthermore, when they have spread to the 
lymph nodes or skin, they may mimic other pathologies such as leishmaniasis, lymphoma, 
and syphilis, among others (Bonifaz et al., 2011).  
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In addition, some of them have been reported outside of the endemic areas (Europe, Japan, 
USA), all cases occurring in immigrants, tourists, or workers returning from endemic 
countries (Buitrago et al., 2011; Poisson et al., 2007).  
For these reasons, it is essential that physicians around the world be informed of the clinical 
characteristics of these fungal diseases in order to include them in their differential 
diagnosis of patients coming from or visiting the recognized endemic areas. 
2. Defining paracoccidioidomycosis (PCM) 
Paracoccidioidomycosis (PCM) is an endemic systemic mycosis caused by the thermally 
dimorphic fungus, Paracoccidioides brasiliensis. The infection is acquired after inhalation of 
the infectious particles (conidia) produced by the fungus’s mycelia form present in its as yet 
unknown natural habitat (Restrepo & Tobón, 2009; Restrepo et al., 2011). This fungal 
pathogen has two morphotypes, a mold at temperatures under 28°C that frequently reveals 
chlamydoconidia and more rarely conidia  (size <5 µm): the latter can transform into yeast 
cells under the influence of body temperature. In tissues and cultures at 35°C–37°C, this 
fungus grows as a yeast resembling a pilot's wheel due to its multiple buds (Figure 1). Yeast 
cells are round to oval but quite variable in size (4–40 µm).  
 
 
Fig. 1. P. brasiliensis budding yeast cells. (A) Pilot’s wheel-like appearance of yeasts observed 
in a lactophenol cotton blue preparation from a colony grown at 36ºC.  (B) Multiple budding 
yeast cells observed in lung tissue with small spheric buds (arrow), attached to or released 
(arrow) from a large mother cell. Confocal indirect immunofluuorescence for fibronectin-
covered P.brasiliensis yeast cells. 
P.brasiliensis is only known in its asexual (anamorph) stage, but through molecular 
techniques it has been classified in the phylum Ascomycota, order Onygenales, family 
Onygenacea, close to Histoplasma capsulatum, Blastomyces dermatitidis, and Emmonsia parva 
phylogenetic tree, all of which have a teleomorphic, sexual stage in the genus Ajellomyces 
(Bialek et al., 2000b; Brummer et al., 1993).  
More recently, the presence and expression of the mating type locus in several isolates of 
this fungus have been reported (Torres et al., 2010). Other studies have revealed that there 
are at least three distinct phylogenetic species, or clades, which are recognized within the 
genus (PS2, PS3, and S1) (Matute et al., 2006). In addition and based on high polygenetic 
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diversity and exclusive morphogenetic characteristics, a different species, designated as 
P.lutzi, has been proposed (Teixeira et al., 2009).  
2.1 General concepts on ecology 
Geography sets PCM apart from other endemic mycoses of the Americas, such as 
histoplasmosis and coccidioidomycosis, as it is strictly confined to Latin America from 
Mexico at 23° North to Argentina at 34° South (Colombo et al., 2011; Nucci et al., 2009; 
Restrepo et al., 2011). The endemic areas are thus contained within the Tropics of Cancer 
and Capricorn (Bonifaz, 2010). PCM, however, is much more frequently reported in South- 
than in Central-American countries respecting Chile, Surinam, the Guyana, Nicaragua and 
Belize and with rare exceptions (one case each in Trinidad, Grenada and Guadeloupe), also 
the Caribbean Islands (Lacaz et al., 2002; Restrepo et al., 2011). Brazil accounts for over 80% 
of all reported cases with Venezuela, Colombia, Ecuador, Bolivia and Argentina informing 
lesser proportion of cases (Colombo et al., 2011; Restrepo et al., 2011). 
Additionally, this mycosis is not distributed homogeneously within a particular endemic 
territory but is concentrated in tropical and subtropical regions with abundant forests and 
waterways, high annual rainfall indices (1400–2999 mm), and mild temperatures (17°C–
24°C) predominating throughout the year (Borelli, 1972; Calle et al., 2001; Restrepo et al., 
2001). Soil texture and moisture availability are also important (Conti-Díaz, 2007; Restrepo et 
al., 2001), as found in Brazil by spatial and ecologic correlate analyses (Simões et al., 2004). 
Studies on this aspect discovered a cluster of juvenile patients with the acute or subacute 
form who were potentially connected to the 1982–83 El Niño Southern Oscillation (ENSO) 
climatic anomalies (Barrozo et al., 2010).  
P. brasiliensis’s microniche has not been pinpointed precisely because the few isolations from 
natural sources have been sporadic, with soil being the substrate most frequently mentioned 
(Franco et al., 2000). Presently, there are indications that the habitat is to be found near 
waterways or in humid areas also propitious to agricultural crops such as coffee, tobacco 
and sugar cane (Calle et al., 2001; Restrepo et al., 2001). One hypothesis postulated that fish 
and aquatic birds would be required around the microniche to allow survival and 
dispersion of the fungus in nature (Conti-Díaz, 2007). Of ecological importance is the regular 
isolation of the fungus from armadillos (Dassypus novemcinctus, Cabassous centralis) captured 
in the endemic areas, some of which revealed internal lesions (Bagaggli et al., 2003). Dogs 
and other domesticated and feral animals have also been implicated (Ricci et al., 2004; 
Richini-Pereira et al., 2008). Nonetheless, P. brasiliensis's microniche remains unknown 
despite many attempts to isolate it from suspected sites such as the permanent areas of 
residence of patients, in and around armadillos' burrows and their foraging areas (Restrepo 
et al., 2001).  
Another circumstance that has hindered tracing the habitat has been the lack of information 
on outbreaks, which could have facilitated detection of the common source of infection 
(Lacaz et al., 2002; Restrepo et al., 2001). An increased number of childhood cases in areas 
where this disorder had previously been considered rare was noted by Coimbra et al. (1994) 
and Gonçalves et al. (1998), who suggested that colonization, gradual felling of the original 
native forests or changes in agricultural practices had probably exposed children to 
aerosolized fungal propagules, leading to increased disease rates. By the same token, in their 
study of 1,000 patients, Bellissimo-Rodrigues et al. (2011) pinpointed an area with the 
highest number of juvenile PCM cases, all of whom had resided close to coffee plantations, 
thereby raising the possibility of aerosol infection through agriculture-related work. None of 
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the above reports, however, mentioned attempts at isolating the fungus from the 
environment.  
Another important blocking factor in the search for the fungus's habitat is its capacity to 
enter prolonged quiescent stages, which has been demonstrated by the approximately 90 
imported cases reported from nonendemic countries, as exemplified by the patients recently 
diagnosed in Europe (Buitrago et al., 2011; Mayayo et al., 2007; Poisson et al., 2007). All 
patients corresponded to emigrants living in Japan, the USA, Canada or several of the 
European countries where they had lived for a mean of 14 years after abandoning their 
native PCM-endemic homelands (Lacaz et al., 2002; Nucci et al., 2009; Shankar et al., 2011). 
These data clearly reveal P. brasiliensis's ability to enter prolonged latency, to revive without 
notice and cause clinically manifested disease. This latency period prompted Borelli to 
create the term reservarea to indicate the site where the primary infection is thought to have 
occurred and distinguishing it from the site, the endemic area, where the infection was 
diagnosed (Borelli 1972).  
2.2 General concepts on epidemiology 
2.2.1 Distribution by age 
The disease is relatively uncommon in children and adolescents with approximately 2% of 
all patients less than 10 years of age and 8% less than 20 years old. (Bellissimo-Rodrigues et 
al., 2011; Paniago et al., 2003; Shankar et al., 2011). Clinically manifested PCM occurs, 
consequently, more often (>80%) in adult patients 30–60 years old with the fourth decade of 
life presenting the largest number of cases (Colombo et al., 2011; Nucci et al., 2009; Paniago 
et al., 2003). The predominance of adult patients is reflected in higher mortality rates for 
those within this age group (Bittencourt et al., 2005; Coutinho et al., 2002; Prado et al., 2009; 
Santo, 2008). Although co-existence of the mycosis with HIV infection is relatively 
uncommon, 4%–5% according to data in the two largest series of cases published in Brazil 
(Belissimo-Rodrigues et al., 2011; Morejon et al., 2009), this dual infection has introduced a 
significant change in age distribution as these patients are younger (mean, 34 years of age) 
than the PCM non-AIDS cases (mean, 45 years of age).  
2.2.2 Distribution by gender 
Gender differences are also important markers of this fungal disorder, with adult males 
exhibiting overt disease much more often than females (Bellisimo-Rodrigues et al., 2011; 
Lacaz et al., 2002; Restrepo et al., 2011). Data taken from different series encompassing 5,500 
patients revealed that 5,045 were males and 455 females for a male-to-female ratio of 11.1 to 
1 (Shankar et al., 2011). In the largest Brazilian series totaling 1,000 patients, the male-to-
female ratio was lower: 6 to 1. It should be noted that important variations have become 
apparent when comparing the series with the lowest ratio of 5.3 to 1 reported in Brazil by 
Blotta et al. (1999) and the highest 70.6 to 1 reported by Shankar et al. (2011) for Colombia. 
These findings indicate that present knowledge is insufficient to explain the male-to-female 
differences according to country of residence and indicate that inter-country variability 
needs further study.  
The difference in the incidence of overt PCM between adult men and women has also been 
explained on hormonal grounds. In 27 women with the mycosis, 70% had menopausal signs 
and in 11% hysterectomy had been performed (Severo et al., 1998). Interestingly, in a series 
of 95 children with PCM collected from various Brazilian reports, there were 51 boys and 44 
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girls for a 1.16 to 1 ratio (Shankar et al., 2011). Such results contrast sharply with the 11.1 to 1 
ratio recorded for overt PCM in adults. Since in children hormonal expression has not yet 
been fully developed, the finding of an almost equal gender distribution in prepubertal 
patients strengthens the protective role of hormones in this fungal disorder. 
Additionally, in the experimental mouse model of PCM infection, differences in male and 
female animals have been noted. The fungus secretes a 17 beta estradiol-binding protein that 
attaches to the female hormone, regulating protein expression and hindering the mycelia to 
yeast transition so that in females fungal development is halted and the infection is 
controlled. On the other hand, in males conidia transform promptly into yeast cells and 
these multiply actively, resulting in progressive infection (Shankar et al., 2011). Additionally 
and as will be explained below, females exhibit a more active cellular immune response 
capable of halting the progress of the infection.  
2.2.3 Distribution by occupation 
Approximately 60% of the patients with active PCM work or have worked in agriculture-
related jobs, notably in tobacco, coffee and sugarcane fields (Calle et al., 2001; Colombo et 
al., 2011; Nucci et al., 2009; Paniago et al., 2003). Other occupations mentioned in large series 
are masonry, bricklaying and mining, as well as lumberjacking in indigenous forests. These 
occupations are, ultimately, associated with inhalation of dust (Conti-Diaz & Calegari, 1979; 
Lacaz et al., 2002; Paniago et al., 2003; Restrepo et al., 2011). Even though residence in rural 
areas is a common trait among PCM patients, migration to urban settlements would be 
accompanied by a change in jobs so that when the diagnosis is established in these 
secondary localities, the medical history may record a different, non-PCM-related 
occupation. Additionally, recent land exploitation methods rely on insecticide application 
and soil burning, as done in sugarcane plantations, which should kill the fungus if present 
in the soil (Nucci et al., 2009; Restrepo et al., 2011). As a consequence, human exposure 
would no longer be as common; however, further observations are required to fully 
understand this point. 
2.2.4 Incidence and prevalence 
Despite the measures being implemented in Brazil, PCM is not yet a reportable disease, with 
the exception of the States of Mato Grosso do Sul, Minas Gerais and São Paulo (Bellissimo-
Rodrigues et al., 2011). Consequently, prevalence and incidence rates are not fully 
dependable. Coutinho et al. (2002) reported an annual incidence rate of 1–3 per 100,000 
inhabitants, and, based on 3,181 deaths known to have occurred as a result of PCM, a mean 
annual mortality rate of 1.45 per million inhabitants was estimated with a nonhomogenous 
spatial distribution among Brazil’s regions and states. The authors concluded that PCM was 
important because it was the eighth cause of death from predominantly chronic or recurrent 
types of infections and parasitic diseases. It also had the highest mortality rate among the 
systemic mycoses but had low visibility. The great majority of deaths occurred in males 
(84.75%) and in the older age groups.  
Bittencourt et al. (2005) analyzed 551 deaths of the mycosis in Parana State, Brazil, with an 
average annual mortality rate of 3.48 per million inhabitants, accounting not only for the 
fifth cause of death among the predominantly chronic infectious diseases, but also the 
highest mortality rate among the systemic mycoses. Santo (2008) reviewed 1,950 PCM death 
certificates finding that the largest number of deaths had occurred in men in the older age 
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groups and among rural workers. The largest series of cases ever published (Bellissimo-
Rodrigues et al., 2011) analyzed 1,000 Brazilian PCM patients and indicated that in the 1980–
1999 period, the incidence rates for the Riberão Preto district in São Paulo State were 
equivalent to a mean of 2.70 cases per 100,000 inhabitants. Colombian estimates show a 
much lower incidence rate, with the highest being 0.24 per 100,000 inhabitants. Since these 
were annual mean mortality rates calculated on the basis of 7,482 deaths reported to be 
caused by PCM, the figures varied from 1.45 to 3.48 per one million inhabitants (Bellissimo-
Rodrigues et al., 2011).  
The importance of this mycosis can be inferred by the high burden of deaths occurring 
among the working population in individuals aged 30–60 years, mostly men engaged in 
agriculture (Bellissimo-Rodrigues et al., 2011). 
2.3 Clinical presentations 
PCM presents a gamut of clinical manifestations grouped according to the organs involved 
and the duration of the disease (Franco et al., 1987; Restrepo et al., 2008). Depending on the 
age and immune status of the host and on the size of the inhaled fungal inoculum, infection 
could be asymptomatic or may give rise to several different forms of disease. In 
immunocompetent individuals, they usually overcome fungal invasion; nonetheless, the 
fungus could remain quiescent, and a latent infection may be established. Four different 
clinical presentations are recognized, as follows. 
2.3.1 Subclinical infection 
After inhalation of the fungal particles, individuals may develop minor pulmonary 
symptoms that cannot be differentiated from those produced by other agents of pneumonia. 
The clinical manifestations often resolve spontaneously without medical intervention; 
however, the fungus could persist in a latent form and may later give rise to disease through 
endogenous reactivation, an event that may coincide with an alteration of the host's immune 
response (Benard et al., 2005). In some cases, the initial infection may leave a residual lung 
lesion. The latter situation presents the so-called regressive form of PCM. The latency 
process is known to exist and is frequently prolonged (mean, 14 years), as revealed by the 
cases reported outside the endemic areas (Buitrago et al., 2011; Walker et al., 2008; Shankar 
et al., 2011). 
2.3.2 Acute/subacute or juvenile-type disease 
This form of the mycosis is the result of the progression of a unresolved initial infection. The 
acute/subacute progressive form is seen mainly in undernourished children and adults less 
than 30 years of age and is the form observed in immunosuppressed individuals, such as 
those with HIV infection. The juvenile form is characterized by predominant involvement of 
the reticuloendothelial system. The mean duration of symptoms at consultation is 60 days 
and the most frequently involved organs are lymph nodes, skin, liver and spleen; less 
frequently bone marrow, stomach, small bowel, bones and joints are also invaded (Benard et 
al., 1994; Londero et al., 1996; Mendes, 1994; Morejon et al., 2009; Pereira et al., 2004). 
2.3.3 Chronic or adult-type disease 
This is the most frequently reported form of PCM, it has a prolonged course (months to 
years) and is diagnosed mainly in patients ranging from 30 to 50 years of age. This clinical 
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form is characterized by significant lung damage as well as extrapulmonary manifestations. 
The respiratory symptoms become apparent only after several years with productive cough 
seen in 50% of the patients. Physical examination reveals few abnormalities even if extensive 
radiographic alterations are noted. The scarcity of respiratory symptoms explains why 
patients seek medical consultation based mainly on extrapulmonary manifestations, such as 
the presence of mucosal and skin lesions (Gomes et al., 2008; Marchiori et al., 2011; Mendes, 
1994; Tuder et al., 1985). Besides the lungs, the most frequently compromised organs are the 
oral mucosa (involving oropharynx and larynx), skin and adrenal glands. Less frequently, 
the nasal and anal mucosa, genital organs and central nervous system may also be attacked. 
Mucosal lesions may be single or multiple, are progressive and destructive, giving rise to 
bleeding and pain, and are accompanied by dysphonia, dysphagia and sialorrhea. 
2.3.4 Residual form 
This form manifests the sequelae of prior disease at a moment when fungal growth has been 
arrested and the patient has overexpressed his immune responses to the point of developing 
fibrosis. This is exemplified by the chronic form of the mycosis where the lungs support the 
most prominent fibrotic changes, a complication recorded in approximately 60% of the 
patients (Funari et al., 1999; Naranjo et al., 1990; Tobón et al., 1995, 2003; Tuder et al., 1985).  
The chronic progressive adult form often precedes the establishment of the residual form. In 
most cases, when the patient is finally diagnosed, this sequela is already present, reflecting 
the corresponding structural and functional alterations (Benard et al., 2005; Bethlem et al., 
1999; Lacaz et al., 2002; Restrepo et al., 2008). It is noteworthy that residual lesions do not 
respond to antifungal treatment. Pulmonary fibrosis is an incapacitating disorder that may 
lead to core pulmonale and, finally, to death (Tobón et al., 2003; Tuder et al., 1985). 
In the differential diagnosis of PCM, various diseases including tuberculosis, 
histoplasmosis, leishmaniasis, malignancies, lymphomatous disorders and certain 
abdominal syndromes should be considered (Campos et al., 2008; Nogueira et al., 2006; 
Ramos & Saraiva, 2008). It is important to note that PCM may coexist with tuberculosis in 
approximately 10% of the cases (Gomes et al., 2008; Quagliato et al., 2007). 
2.4 Establishing the diagnosis 
Diagnosis of PCM is based on the identification and isolation of the fungus. The microscopic 
visualization in representative clinical samples (including respiratory specimens or biopsies) 
of multiple budding yeast cells with a pilot’s wheel-like appearance by direct KOH 
preparations or special stains, establishes the diagnosis (Lacaz et al., 2002; Nucci et al., 2009; 
Restrepo et al., 2009, 2011). Isolation of the fungus in culture is considered the gold standard 
and is successful in 60–85% of the cases. Additionally, serologic and immune-based tests 
[including agar gel immunodiffusion, complement fixation, enzyme-linked immunosorbent 
assays (ELISA) and antigen detection] are also frequently employed. These laboratory tests 
have great value and can also be employed in follow-up studies (Gómez et al., 1997, 1998; 
Lacaz et al., 2002; Nucci et al., 2009; Restrepo et al., 2009, 2011). In addition, in the last 
decade, molecular tests to diagnose PCM have been implemented; these tests require further 
research (Buitrago et al., 2011; Gomes et al., 2000; Bialek et al., 2000a; Koishi et al., 2010). 
2.5 Therapeutic options 
Treatment of PCM should be implemented according to the disease form; in addition, 
adequate nutrition, control of associated diseases, and measures to stop smoking must be 
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implemented. Treatment of this mycosis includes sulfonamides, amphotericin B and azoles 
(Quagliato et al., 2007). Thus, in the case of minor and moderate forms of PCM, the 
combination of trimethoprim-sulfamethoxazole can be used (Shikanai-Yasuda et al., 2008). 
In cases of severe illness, treatment must be implemented using amphotericin B and 
continued with an oral antifungal, preferably itraconazole (Quagliato et al., 2007). Among 
the azoles, the latter is the drug of choice as it is effective in 98% of cases, irrespective of the 
clinical form, and has a low relapse rate (3%) (Naranjo et al., 1990; Shikanai-Yasuda et al., 
2002). Nonetheless, it may not be possible to eradicate the etiologic agent completely, and 
the risk of endogenous reactivation may persist. Treatment of PCM is prolonged, usually 
taking 6 months to 1 or maximum 2 years, but in general it should continue until clinical 
manifestations are resolved, except for those due to residual fibrotic sequelae (Hahn et al., 
2000; Shikanai-Yasuda et al., 2002). 
3. Pathogenesis of experimental PCM in mice 
Animal models are excellent tools to study the pathogenesis of the different infectious 
diseases. In order to understand the pathogenesis of PCM, different animal models of this 
mycosis have been established, using different hosts such as mice (Calich et al., 1985; Cano 
et al., 2000; Defaveri et al., 1982; McEwen et al., 1987; Moscardi & Franco, 1980), hamsters 
(Essayag et al., 2002; Iabuki & Montenegro, 1979; Peraçoli et al., 1982), guinea pigs (Fava-
Netto et al., 1961) and rats (Iovannitti et al., 1999). All of these are powerful tools to explore 
the molecular and cellular aspects of PCM pathogenesis. The ability to control multiple 
variables in the establishment of the experimental models allows simulation of the human 
disease states and monitoring their course quantitatively. Therefore, animal models are a 
useful alternative to study the kinetics of the mechanisms involved in the pathogenesis of 
PCM.   
3.1 Establishment of a pulmonary PCM model induced by Pb-conidia 
Problems determining the initial stages of the host–P. brasiliensis interaction in humans 
when the fungal habitat is unknown indicate that an animal model of pulmonary PCM that 
would mimic, as closely as possible, human disease is needed. Such a model was established 
by the intranasal administration of Pb-conidia to male BALB/c mice to be studied 
sequentially during the course of infection (McEwen et al., 1987; Restrepo et al., 1992). In this 
model, we have determined certain immune, histological and radiological aspects of 
pulmonary lesions by histopathology (early and chronic periods) (González et al., 2008a, b, 
c; Lopera et al., 2010, 2011) as well as by high-resolution computed tomography-HRCT 
(chronic periods) (Lopera et al., 2010). The local immune response has been measured by 
determining different cytokines in supernatants of pulmonary homogenates (González et 
al., 2003, 2005b, 2008d; Naranjo et al., 2010).  
3.2 Early immunological and histopathological findings in the model 
It has been hypothesized that once P. brasiliensis conidia reach the lung, they interact initially 
with the extracellular matrix (ECM) proteins (expressed predominantly in lung tissue), lung 
epithelial cells (which also express these ECM proteins on their own surface), alveolar 
macrophages (Ms) and pulmonary dendritic cells. In addition, it has been reported that the 
different fungal morphotypes of P. brasiliensis (conidia, yeast cells and mycelia) exhibit on 
their surface adhesin-type molecules that allow both binding to several ECM proteins – 
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mainly fibronectin, fibrinogen and laminin – and adherence to epithelial cells (Caro et al., 
2008; González et al., 2005a, 2008a, b; Hernández et al., 2010). Activation of pulmonary cells, 
mainly Ms, took place after fungal interaction, thus initiating the inflammatory process 
through production of pro-inflammatory cytokines and chemokines, which in turn induced 
the expression of adhesion molecules on the leukocytes' surface (González et al., 2003, 
2005b).   
3.2.1 Early pulmonary inflammatory process    
During the first 4 days post-infection, an acute inflammatory process, composed mainly of 
polymorphonuclear neutrophils (PMNs) and Ms, was observed in the lungs (Cock et al., 
2000; González et al., 2003, 2005b; Restrepo et al., 1992). At the histopathological level, this 
inflammatory event concurred with a bronchopneumonic process in which PMNs and Ms 
accumulated and fused with each other to constitute extensive, ill-defined masses, located 
inside the alveolar and the surrounding peribronchiolar spaces, resulting in involvement of 
approximately 40% of the lung’s area (Cock et al., 2000; González et al., 2005b; Restrepo et 
al., 1992). It should be noted that during the first 3 days post-challenge, eosinophils and 
lymphocytes were also observed at the perivascular level (González et al., 2005b). After the 
4th day post-challenge, the cellular infiltrate was replaced by mononuclear cells, mainly Ms. 
The results of additional studies conducted in bronchoalveolar lavage fluids (BALs) 
coincided with the in situ description, with predominance of PMNs and Ms during the 
period indicated (González et al., 2003). Interestingly, at the end of the 2nd week post-
infection, the inflammatory process decreased, indicating transient control of fungal 
invasion (González et al., 2005b).  
Similarly, high levels of pro-inflammatory cytokines [interleukin (IL)-1, IL-6, tumor 
necrosis factor-alpha (TNF-) and chemokine, macrophage inflammatory protein (MIP)-2)] 
were recorded, especially in the pulmonary compartments and during the first 4 days post-
challenge, (González et al., 2003). The production of these molecules by both inflammatory 
and endothelial cells accounted for the recruitment of certain inflammatory cells indirectly 
through induction of adhesion molecule expression, which in turn mediated migration of 
the inflammatory cells into the injured tissue (Tracey & Cerami, 1994). In accordance with 
the above results, a significant decrease in the mouse pulmonary fungal burden occurred 
after the first 2 days post-challenge (Cock et al., 2000; González et al, 2005b).  
3.2.2 Expression of adhesion molecules and extracellular matrix proteins in the lungs 
Adhesion molecules expressed on the cell’s surface of both leukocytes and endothelial cells 
are important mediators in the recruitment of leukocytes to sites of inflammation including 
the lungs (Albeda et al., 1994; Pilewski & Albelda, 1993). Expression of these adhesion 
molecules is induced by the production of pro-inflammatory cytokines such as TNF- and 
IL-1 (Osborn et al., 1989; Masinovsky et al., 1990), which have been reported as important 
inflammatory components in a variety of lung diseases including those caused by fungi 
(Hamacher & Schaberg, 1994; Izzo et al., 1998; Yokomura et al., 2001; Yu & Limper, 1997). In 
our PCM mouse model, we have observed that lungs of mice infected intranasally with 
P.brasiliensis conidia show a higher expression of adhesion molecules during the first 4 days 
post-challenge. Thus, the intercellular adhesion molecule-1 (ICAM-1) was overexpressed 
mainly on bronchiolar epithelium, vascular endothelium, pneumocytes and Ms; the 
vascular cell adhesion molecule-1 (VCAM-1) was also overexpressed but only in the 
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vascular endothelial cells, while CD18 and Mac-1, two molecules belonging to the 2 
integrin family, were strongly expressed on PMNs and Ms (González et al., 2005b). 
In lungs of mice infected with P. brasiliensis conidia, an initial deposition of fibrin-like 
material was detected after 2 days post-infection. In addition, an increased deposition and 
rearrangement of the following ECM proteins – laminin, fibronectin, fibrinogen, collagen 
and proteoglycans – were observed not only at the beginning of infection, but also during 
the late periods of fungal infection (González et al., 2008c). Interestingly, this increased 
deposition of ECM proteins in the lungs of infected mice was accompanied by a marked 
afflux of pro-inflammatory cells (González et al., 2008c).  
In addition, P. brasiliensis is known to express adhesin-like molecules on its surface that 
recognize and bind to ECM proteins (Barbosa et al., 2006; González et al., 2005a). More 
recently, in elegant experiments using antisense technology, the role of a P. brasiliensis-
adhesin molecule was confirmed when a 32-kDa protein, a putative adhesion member of the 
haloacid dehalogenase (HAD) superfamily of hydrolases, conferred both adherence capacity 
to pulmonary human epithelial cells and virulence in a mouse model of infection 
(Hernández et al., 2010) 
The observations described above may suggest that ECM proteins modulate the 
pathogenesis of PCM by means of two mechanisms: 1) participation in the migration of pro-
inflammatory cells into the lungs and 2) serving as a binding protein for P. brasiliensis 
expressing on its surface adhesin-like molecules (receptors). These interactions may serve 
the fungus both for attachment to host tissue (evading the physical barriers) and 
dissemination to other organs, contributing in this manner to the establishment of the 
disease process. 
3.2.3 Expression by pulmonary phagocytes of microbicidal molecules 
During any infectious process, phagocytic cells are the main effector cells, which upon their 
activation (e.g., by cytokines), produce microbicidal substances [i.e., degradative enzymes, 
defensins, lysozymes, reactive oxygen intermediates (ROS) and reactive nitrogen 
intermediates (RNI)] capable of inhibiting and destroying several pathogens (Nathan & 
Shiloh, 2000; Newman et al., 2000).  
Taking into account that both PMN and Ms are the principal components of the pulmonary 
inflammatory infiltrate of mice infected with P. brasiliensis conidia, the expression of 
microbicidal molecules produced by these phagocytic cells in the PCM model was 
determined. In vivo studies failed to detect nitric oxide (NO) production or inducible nitric 
oxide synthase (iNOS, the enzyme responsible for NO production) during the early days 
post-challenge in the lungs of mice infected with P. brasiliensis. Interestingly, as will be 
described below, a higher expression of iNOS was observed in the late periods of infection 
(González et al., 2008d). In additional studies, we observed an increase of in situ lysozyme 
expression (PMN and Ms) in the lungs of mice infected with P. brasiliensis conidia during 
the first 4 days post-challenge. This expression was accompanied by a decrease in the 
number of fungal propagules (González et al., 2008), observations suggesting that 
lysozymes may exert an antifungal effect against P. brasiliensis. 
Altogether, the above observations led us to propose a description of the initial mechanism 
triggered by the infection with P. brasiliensis conidia:  
1. Once the conidia reach the lungs, they adhere to both ECM proteins and epithelial cells 
through the interaction with adhesins present on their own surface; in addition, the 
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fungal cells may interact with alveolar Ms or dendritic cells present on the alveolar 
space.  
2. Once the adhesion process or the cellular interaction takes place, induction of the 
production of pro-inflammatory cytokines takes place, which in turn stimulates the 
expression of adhesion molecules with such expression modulating the migration of 
circulating inflammatory cells into the lung tissue. This event triggers a strong 
inflammatory process, enhancing cytokine and chemokine production as well as 
increasing the deposition and rearrangement of ECM proteins.  
3. P. brasiliensis conidia will experience a transitional process to yeast cells if no inhibitory 
mechanism intervenes in such process.  
4. Once the phagocytes are activated, they will express, or produce, microbicidal 
molecules capable of destroying the fungus.  
5. If the fungus is able to overcome the fungicidal mechanisms exerted by the host's 
defenses, dissemination to other organs will occur, perhaps using their adhesins to bind 
to ECM proteins or by producing degradative enzymes able to cleave such ECM 
proteins. Finally, the disease process will become established. 
3.3 Chronic immune responses in the model 
The intranasal inoculation of P. brasiliensis conidia into BALB/c male mice resulted in a 
progressive disease characterized by an increase of CFUs in the lungs, with maximal values 
at the 12th and 16th week’s post-infection (Franco et al., 1998). In addition, extrapulmonary 
dissemination to the spleen (week 4) and liver (week 12) will take place, as indicated by the 
isolation in culture of the fungus from these organs (McEwen et al., 1987). 
Then, during the infectious process corresponding to the chronic stages, different 
immunological mechanisms such as inflammatory responses, cytokine production, 
metalloproteinase expression, nitric oxide participation, granuloma formation and, finally, 
the chronic pulmonary sequelae characterized by fibrosis enter into play, as described 
below.  
3.3.1 Production of cytokines 
Additionally, several studies on the cytokines implicated in the chronic stages of 
experimental PCM have demonstrated, through ELISA assays and the Multiplex system, 
that from the 4th to the 8th week post-challenge, infected mice exhibited a significant increase 
in IL-1, TNF-, IL-12p40, RANTES, MIG, PDGF-b, IL-13 and TGF-. Even though these 
cytokines have been implicated in the formation and maintenance of granuloma, some of 
them (IL-1, TNF-, IL-13 and TGF-) are also directly involved in fibrosis generation 
(Franco et al., 1998; Lopera et al., 2011; Naranjo et al., 2011; Wynn, 2007).  
Other authors, using both male and female mice in a PCM experimental model, have shown 
different immune responses that are gender-dependent with high production of Th1 cytokines 
and T-beta expression by the paracoccin-stimulated cultures of spleen cells from infected 
female mice; in contrast, cells from infected males produced higher levels of the Th2 cytokines 
and expressed GATA-3 (Pinzan et al., 2010). These results were confirmed using mice that had 
been submitted to gonadectomy followed by inverse hormonal reconstitution, where spleen 
cells derived from castrated males reconstituted with estradiol had produced higher levels of 
IFN-γ and lower levels of IL-10 than normal males in response to paracoccin stimulus. In 
contrast, spleen cells from castrated female mice that had been treated with testosterone 
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produced more IL-10 and less IFN-γ than cells from normal females (Pinzan et al., 2010). In 
conclusion, these results reveal that the sexual hormones had a profound effect on the biology 
of immune cells, with estradiol favoring protective responses against P.brasiliensis infection. 
3.3.2 iNOS expression and nitric oxide (NO) production in the lungs 
In this PCM pulmonary model, the role of the NO system was determined during the 
chronic immune response by means of lung biopsies from infected mice. We developed an 
immunohistochemical stain for iNOS (NOS2) and observed that this enzyme was expressed 
mainly in vivo by the epithelioid histiocytes, with its maximal expression occurring 12 weeks 
after infection (González et al., 2008d). The expression of iNOS correlated significantly 
(r=0.77891) with the number of granulomas present in the pulmonary parenchyma 
(González et al., 2008d), suggesting that at this stage iNOS induction may depend on factors 
or mechanisms related to the environment in the granuloma (Goldman et al., 1996).  
In addition, the in vivo administration of aminoguanidine (a highly specific inhibitor of 
iNOS) to P. brasiliensis-infected and noninfected mice induced in the former a significant 
reduction of their survival in comparison with negative control mice. These results suggest 
that during the chronic stages (12–17 weeks post-infection), the NO system played an 
important protective role against fungal infection (González et al., 2008d). This effect has 
also been observed in a model of latent tuberculosis (Flynn et al., 1998). However, 
Nascimento et al. (2002) proposed a dual role for nitric oxide in another experimental PCM 
model, where NOS2-derived NO would be essential for resistance to the fungus, but its 
overproduction would be associated with susceptibility. 
Using NOS2-deficient mice, Livonesi et al. (2009) demonstrated that this enzyme is to be 
considered as a resistance factor during experimental PCM because it controls fungal 
proliferation, cytokine production, development of a high inflammatory response and 
consequently formation of necrosis. Other authors demonstrated that NO has an important 
role in granuloma modulation, by controlling osteopontin and MMP production, as well as 
by inducing loose granuloma formation and fungal dissemination, resulting, at later phases, 
in progression of experimental PCM (Nishikaku et al., 2009). However, iNOS-derived NO 
seems not to be the sole factor responsible for the immunosuppression observed during the 
infections caused by P. brasiliensis. 
3.3.3 Granulomatous inflammation in the lungs during experimental PCM 
The granuloma is the histologic hallmark of a variety of infectious and noninfectious 
processes, including PCM, all of which elicit chronic granulomatous inflammation. The 
word “granuloma” is derived from the Latin word granulum, which means a small particle 
of grain and, traditionally, is microscopically described as a compact, rounded aggregate of 
Ms usually surrounded by a rim of lymphocytes that results in a response to chronic 
antigenic stimulation. Aggregation of Ms is the minimum requirement of a granuloma, 
regardless of whether the lesion also contains necrosis, lymphocytes, plasma cells, or 
multinucleated giant cells (Mukhopadhyay & Gal, 2010). The granuloma functions both as a 
niche in which some microorganisms can grow or persist and as an immunologic 
microenvironment in which cells interact to control and prevent dissemination of the 
eliciting pathogen (Flynn et al., 2011). 
Pulmonary granulomatous inflammation in experimental PCM is a dynamic process that 
goes from dispersal parenchymal inflammation, to well-defined nodules, from periarterial 
www.intechopen.com
 Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
371 
sheath inflammation to pseudotumoral masses (Figure 2) (Lopera et al., 2011). The lung’s 
area occupied by the inflammatory reaction increases gradually from 8 to 12 weeks after 
P.brasiliensis infection, involving up to 40% of the lung’s area. In the following subsections, 
we will describe the structure and cellular composition of granuloma during the 
experimental infection; review the formation and maintenance of the granuloma reported in 
the literature and compare the main features of human and experimental pulmonary 
histopathology during the course of P. brasiliensis infection.  
 
 
Fig. 2. Pulmonary lesions observed in BALB/c mice infected with P. brasiliensis conidia. (A) 
Well-defined nodules. (B) Confluent granulomas. (C) Periarterial sheath inflammation. (D) 
Dispersed parenchymal inflammation. H&E stained slides, 10X.   
Structure and cellularity of pulmonary lesions: The well-defined granuloma or the nodular 
pattern corresponds to multiple sphere-like or oval parenchymal granulomas adjacent to 
terminal bronchioles, about 400 µm in diameter, sometimes isolated but becoming confluent 
as infection progresses. This is the predominant pattern throughout the infectious process in 
the lungs of BALB/c mice infected with P. brasiliensis conidia. In humans and experimental 
PCM, the general structure of granuloma consists in two distinct zones: one noncollagenic 
central zone composed of P. brasiliensis yeasts and Ms, and one peripheral zone composed 
by lymphocytes and fibroblastoid-like cells (Kerr et al., 1988). However, the cellularity and 
pattern of lesions change as infection progresses. A summary of the main structural and 
cellular changes in the granulomas sequentially observed in the experimental model of PCM 
is presented below (Lopera et al., 2011).  
During the early stages of granuloma development, 4 weeks post-infection in our 
experimental model, granulomas were composed of a central core or zone of Ms and fungi 
with a frequent and intense infiltration by PMNs, sometimes presenting an apoptotic aspect. 
Some Ms formed multinucleated giant cells. The central zones of the granulomas were 
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surrounded by a fibroblast-like layer expressing concentric layers of reticular fibers with a 
lesser amount of interstitial collagen. The peripheral zone consisted of a noncontinuous halo 
of small lymphocytes, at times forming pseudofollicular lymphocyte aggregates. At this 
time, an intense and diffuse parenchymal inflammation, disposed near or around the 
granulomas, accompanied the pulmonary response to P. brasiliensis. 
During the most chronic stages of the infection (8, 12 and 16 weeks), Ms acquired a 
xanthomatous aspect, cholesterol crystals appeared in the central zone of the granuloma and 
a large number of mature plasma cells located at the periphery and mixed with the 
fibroblastic-like cells were observed. Besides well-defined granulomas, the peak of 
inflammation (8–12 weeks p.i.) was characterized by periarterial inflammation accompanied 
by lymphatic dilatation and edema. The cellular infiltrate defined the periarterial 
inflammatory sheaths with dispersed fungi (Figure 3) and more mature plasmocytes and 
eosinophils in comparison with the granuloma.  
 
 
Fig. 3. Fungal aspects as seen in the lesions of a mouse with experimental pulmonary PCM. (A) 
Nodule full of fungi in the central area (10X), that present multiple-budding yeast cells with 
varying sizes (insert 100X). (B) Numerous fungi spread all over the periarterial space (10X), 
several of them presenting a special perifungal space (insert 100X).  Grocott’s stained slides. 
Multiple granulomas fused and formed pseudotumoral masses or “paracoccidioidomas” 
five to six times larger than nodules (2,000 ± 194 µm in length) were observed in the final 
period of evaluation (16 weeks p.i.) in this experimental model. 
Formation and maintenance of P. brasiliensis-induced granuloma: The mechanisms that drive the 
migration of cells that will form and maintain the granuloma around P. brasiliensis have 
begun to be explored. However, important differences in the experimental models as 
concerns the infective propagules (conidia, yeast cells) and the fungal isolates used, as well 
as the route of inoculation and the experimental host’s genetic background, makes 
conclusions difficult. Table 1 presents the main results of research that has analyzed the 
cells and mediators involved in P. brasiliensis-induced granulomatous inflammatory 
response centered on pulmonary findings.  
The major biological significance of granuloma is the limitation of the infection to a local 
area . However, diffuse and loose granulomatous inflammation does not limit infection  and 
is associated with incapacity to control the disease, as shown by the large number of fungal 
cells and the diminished survival time of infected animals (Livonesi et al., 2008, 2009).  
An inflammatory response is necessary for disease control but it is also responsible for the 
typical immunopathology caused by diseases such as PCM that include tissue necrosis and 
cavitations in the center of granulomas.  
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Experimental model Main results Reference 
Male BALB/c mice infected i.n. 
with 26×106 viable or heat-
killed P.brasiliensis yeasts; or 
inoculated with 6.5×106 
nonviable fragmented yeast 
cells 
Granuloma formation required viable yeast cells or 
conidia. Heat-killed Pb yeasts or yeast fragments did 
not induce granuloma formation. 
(Bedoya et al., 
1986; Cock et 
al., 2000) 
Rats infected i.p. with 
P.brasiliensis  yeasts 
Although most lesions developed in peritoneal cavity, 
granulomas also appeared in lung.  
Pulmonary granulomas were less collagenic than 
those observed in omentum, diaphragm and liver. 
(Kerr, et al., 
1988) 
Male C57Bl/6 mice and IFN-γ 
and TNF receptor p55-deficient 
mice infected i.v. with 1×106 
P.brasiliensis yeast cells 
IFN- and TNF receptor p55-deficient mice were not 
able to build organized granulomas, presented greater 
number of fungi and high rates of mortality. 
(Souto et al., 
2000) 
Male C57BL/6 and ICAM-1KO 
mice infected i.t. with 1×106 Pb 
18 yeast cells 
ICAM-1 was required for the early formation of 
granulomas. In the absence of ICAM-1, granuloma 
development delayed 60 days vs. 30 days in control 
mice. 
(Moreira et al., 
2006) 
In vitro granuloma model 
induced by gp43-coated beads 
In vitro granuloma formation required B1-cells and 
Ms interaction. Ms alone were not able to migrate 
to the beads and form granulomas. Soluble gp43 
antigen-enhanced granuloma-like structure 
formation.  
(Vigna et al., 
2006) 
BALB/c and BALB/Xid mice 
infected i.t. with 1×106 Pb18 
yeast cells 
Mice deficient in B1-cells (BALB/Xid mice) exhibited 
smaller pulmonary granulomas with less fungi and 
longer survival. Therefore, B1-cells participated in the 
exacerbation of granulomatous lesions and increased 
host susceptibility to infection. 
(Popi et al., 
2008) 
C57BL/6 IL-12p40−/− and WT 
mice infected i.v. with 1×106 
Pb18 yeast. 
In the absence of the IL-12p40 subunit, involved in 
both IL-12 and IL-23 formation, mice developed high 
number of pulmonary granulomas without defined 
delimitations associated with high number of yeast 
cells.  
(Livonesi et al., 
2008) 
C57BL/6 iNOS−/− and WT mice 
infected i.v. with 1×106 Pb18 
yeast 
iNOS−/− mice showed granulomas with high 
inflammatory response, central necrotic areas, diffuse 
distribution of cells, incipient reticulin fiber pattern 
and high number of yeast cells.  
(Livonesi et al., 
2009) 
BALB/c male mice infected i.n. 
with 4×106 P.brasiliensis conidia 
Extracellular matrix proteins overexpressed and 
suffered rearrangement process during the course of 




Abbreviations:  i.n.: intranasally, i.p.: intraperitoneally, i.t.: intratracheally i.v.: intravenously, Pb: P. 
brasiliensis, WT: wild-type 
Table 1. Contribution of cell subsets and molecules in pulmonary granuloma formation 
following infection with P. brasiliensis.  
3.3.4 Fibrosis as sequelae of PCM disease 
Pulmonary fibrosis is detected in several disorders with known or unknown etiologies 
(Datta et al., 2011). In this sense, this progressive and prominent complication is also 
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observed in approximately 60% of patients suffering from the chronic form of PCM 
(Restrepo et al., 2008). Given that the P. brasiliensis microniche remains uncharacterized and 
taking into consideration the prolonged latency observed in PCM, the characteristics of the 
primary infection have not been defined, and great difficulties have arisen when 
sequentially evaluating the development of fibrosis attributed to this infection in humans. 
However, results from the experimental pulmonary PCM model have given convincing 
evidence as to the progress of this disease (González et al., 2008b).  
In contrast with idiopathic pulmonary fibrosis (IPF) for which current research indicates that 
inflammation is of lesser importance with fibrosis appearing primarily as a disorder of 
fibroblast proliferation and activation in response to an as yet unknown trigger (Meltzer & 
Noble, 2008), the development of fibrosis in PCM is a progressive event, resulting from a 
persistent antigenic stimulus leading to chronic inflammation and establishment of fibrosis 
mainly located in the perihilar region, the main bronchi and their branches, and the large 
pulmonary vessels (Restrepo et al., 2011). The functional limitation caused by the 
development of fibrosis may advance toward cor pulmonale, progressive lung incapacity 
and finally death (Restrepo et al., 2008; Tobón et al., 2003; Tuder et al., 1985). 
The fibrosis process begins with acute injury caused by the interaction of P. brasiliensis 
conidia with ECM proteins and lung epithelial cells; this interaction is followed by chronic 
granulomatous inflammation with fibroblast proliferation and activation, an increase in 
ECM proteins predominantly composed of fibronectin, fibrinogen, collagen type I and III, as 
observed in the surroundings of the granulomas. 
These EM proteins contribute to the establishment of fibronodular lesions that continue to 
advance even after appropriate antifungal therapy with itraconazole, a medication that 
effectively controls the active stage of this mycosis but does not hinder lung fibrosis 
(González et al., 2008a, c; Naranjo et al., 2010; Tobón et al., 2003).  
Even though patients with chronic PCM show well-established pulmonary lesions at 
diagnosis, all of them are not in the same stage of infection development, explaining why, 
although not sequentially, several studies have been able to describe certain histological 
patterns present during the development of fibrosis in humans. Tuder et al. (1985) described 
the lungs of 12 patients with chronic PCM in histopathological terms and concluded that 
chronic pulmonary PCM is a disease that affects both lungs equally and that fibrosis is 
mainly related to the progressive course of the granulomatous reaction to cicatrization and, 
to a lesser degree, is probably due to direct induction by the fungi. This study described 
extensive areas of dense fibrosis close to the hilar region and involved structures such as the 
bronchi and lymph nodes with fibrosis extending as fibrous septa of variable thickness 
throughout the lung parenchyma (Tuder et al., 1985).  
With the development of HRCT, several studies have been published demonstrating the 
correlation between histopathological and radiological findings, thus providing a more 
precise characterization of the pattern and magnitude of the lung abnormalities, as well as 
better follow-up of patients with chronic pulmonary PCM. In regards to fibrotic findings on 
chest tomography, this process has been described as thickening of interlobular and alveolar 
septa, primarily those interconnecting the granulomas (Marchiori et al., 2011). This has been 
correlated histopathologically with prominent collagen deposition, especially near the hilar 
regions, comprising lymph nodes, bronchi and the main pulmonary artery branches; 
additionally, pulmonary architectural alterations were also observed (Funari et al., 1999; 
Marchiori et al., 2011; Souza et al., 2006).  
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Notwithstanding, in some patients, fibrosis development has been recorded in the absence 
of a clearly established granulomatous reaction, thus allowing speculation that the fungus 
itself might induce an active and higher collagen deposition (Marchiori et al., 2011; Tuder et 
al., 1985). 
In reference to PCM animal models, several have been developed with the purpose of 
understanding the complete course of the disease; despite differences on the inoculum used 
(infective forms and concentration), fungal isolates, route of inoculation and host genetic 
background, the results have made it possible to define certain common phases during the 
granulomatous inflammation process (Burger et al., 1996; Calich et al., 1985; Da Silva et al., 
2009; Xidieh et al., 1999). However, only the murine model of chronic pulmonary PCM in 
male BALB/c mice induced by the intranasal inoculation of naturally infective conidia has 
provided a reproducible model to observe in detail not only the characteristics of the 
inflammatory response induced by P. brasiliensis conidia, but also the important components 
of the PCM residual form (Cock et al., 2000; González et al., 2008a; Restrepo et al., 1992).  
In the murine model described above, it was determined that at 4 weeks post-infection, 
when the granuloma are well shaped, thin fibers of collagen and reticulin became evident, 
suggesting the beginning of a fibrotic process, which progressed simultaneously with the 
presence of leukocyte infiltrates surrounding the granuloma (Lopera et al., 2010). After the 
8th week post-infection, thick fibers of collagen and reticulin became evident as an indicator 
of established fibrosis; fibers of both proteins gradually increasing up to 12 weeks post-
infection indicated the collagenesis process reaching its highest intensity, with particular 
involvement of the periarterial space and the surrounding area of the granuloma (Figure 4), 
whether or not it was confluent. Observations made in the 16th week post-infection revealed 
a well-established pulmonary fibrosis process (González et al., 2008b, c; Lopera et al., 2010; 
Naranjo et al., 2010). 
 
 
Fig. 4. Characteristics of lung fibrosis in P. brasiliensis infected mice.  (A) Increased collagen 
(red fibers) noticed in the periarterial inflammatory reaction (thin arrow), in the periphery of 
granulomas (thick arrow) and in the bronchial wall (arrow's head). (B) Panoramic view of 
the entire lung. (C) Detail of collagen fibers deposition in the periphery of a granuloma and 
around a bronchus. Picrosirius and fast green (PIFG) stained lung sections. (Scale bars: A = 
100µm, B = 2mm and C = 30µm).  
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One of the pathogenic mechanisms involved in the progressive accumulation of collagen 
and later development of fibrosis could be the disproportion between synthesis and 
degradation of ECM components such as reticulin and collagen, primarily due to an 
imbalance among the mediators of matrix degradation, metalloproteinases (MMPs) and 
their inhibitors (Garcia-de-Alba et al., 2010; Pardo & Selman, 2006). The presence of MMPs, 
specifically collagenase MMP-1 and gelatinase-A MMP-2, and the tissue inhibitors of MMPs 
(TIMP-1) was evaluated using immune stain in the murine model of pulmonary PCM. The 
results indicated that 4 weeks after P. brasiliensis intranasal inoculation, 85% of infected mice 
expressed MMP-1 as MMP-2 and 71% of them expressed TIMP-1, both with moderate 
intensity; at 16 weeks post-infection, almost all them showed equally positive immune stains 
to the TIMP-1 and MMPs evaluated, with the difference that close to 37% of them exhibited 
high stain intensity (Bárcenas et al., 2004). The immune stain was observed on epithelial 
alveolar cells and alveolar Ms located in peribronchial tissue, although by immune 
staining, it was not possible to observe an imbalance between MMPs and TIMP-1. This 
study suggested that as more collagen becomes deposited, more activity of MMPs and their 
inhibitors will be present. 
Although much remains to be done, the results offered by animal models have contributed 
greatly to understanding the genesis of the fibrotic process in PCM. 
3.3.5 Experimental attempts to control fibrosis 
Although currently several antifungal drugs are available for the treatment of PCM, as 
mentioned above in the diagnosis and treatment sections, the majority of them require 
prolonged therapies oscillating between 1 and 2 years (Borges-Walmsley et al., 2002). 
Additionally and even though these antifungal drugs can arrest the progression of the 
infection by restricting fungal proliferation, the principal sequelae of PCM, pulmonary 
fibrosis, persists, and it has been observed in both humans and murine models (Naranjo et 
al., 2010; Tobón et al., 2003). The fibrosis process generates progressive lung incapacity and 
it is probably a source of P. brasiliensis in future relapses of the disease (Borges-Walmsley et 
al., 2002). For these reasons, the need to search for new drugs or for the implementation of 
combined therapies has been indicated (Pappas, 2004), including experiments aiming to 
prevent or at least reduce the appearance of this serious sequela. 
According to the recommendations given by the American Thoracic Society, the basic 
therapy for the treatment of patients suffering from pulmonary fibrosis includes certain 
immunosuppressive drugs based on the theory that the development of fibrosis is 
attributable to persistent inflammatory stimulus. However, the effect of using this kind of 
medication in humans with the chronic form of PCM remains unknown. 
Recently, we evaluated the effect of two combined therapies (itraconazole + prednisolone) 
and (itraconazole + pentoxifylline) on the development of fibrosis using our murine model 
of pulmonary PCM, which reproduces the human infection from its inception until reaching 
the chronic form (Naranjo et al., 2011). In this study, the azolic derivative (itraconazole) was 
used because it is the antifungal treatment of choice for PCM (Restrepo et al., 2011; Shikanai-
Yasuda et al., 2006). In reference to the combined itraconazole + prednisolone therapy, the 
authors reported that although a significant reduction in both granulomatous inflammation 
and development of fibrosis was observed when this combined therapy was used, once it 
was ended, the fibrotic process reappeared and progressed over the levels observed when 
treatment with itraconazole alone was given. On the contrary, the use of itraconazole 
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combined with pentoxifylline, a methylxanthine compound with recognized immune 
modulatory properties (Inoue et al., 2004; Tong et al., 2004) and antifibrotic effects when 
acting on fibroblast cells (Fang et al., 2003; Romanelli et al., 1997; Valente et al., 2003), 
generated good results. 
The combined itraconazole + pentoxifylline therapy promptly reduced the granulomatous 
inflammation and caused a significant and rapid decrease of both thin reticulin and collagen 
fibers. The most important result was that thick fiber deposition of these proteins, which are 
considered fibrosis indicators, was reduced to normal levels, as seen in the uninfected mice, 
and remained low even after the end of the treatment. Considering fungal loads, it was 
demonstrated that the addition of pentoxifylline to itraconazole treatment did not produce 
additional deleterious effects on itraconazole antifungal activity; on the contrary, a tendency 
towards a faster reduction of fungal burdens was observed when the combined therapy was 
used (Naranjo et al., 2011). These beneficial effects were noted even when such combined 
therapy was started belatedly at 8 weeks post-infection, a time at which the fibrosis process 
was already established in the murine model. 
The fact that in mice the combined itraconazole + pentoxifylline therapy promptly reduced 
the development of pulmonary fibrosis to levels lower than those seen with antifungal 
therapy alone, and that this effect was maintained even after treatment termination, presents 
a promising advance in the development and establishment of adjunctive immunotherapies 
for the treatment not only of pulmonary chronic PCM but also of several disorders or 
chronic infections that lead to the development of fibrosis.   
These findings could imply not only a reduction of treatment costs but, more importantly, 
improvement in the chronic pulmonary PCM patients' quality of life. 
4. Pulmonary histopathology in patients with PCM: The counterpart of the 
experimental infection 
Reports on the pathologic features of pulmonary lesions in patients with the chronic adult 
form of PCM are scarce in the literature. The classical report was published by Tuder et al. 
(1985), who described five main pathologic aspects in the lungs of 12 patients with PCM as 
follows:  
1. Pneumonic reaction characterized by acute alveolitis with histiocytes, few PMNs, 
lymphocytes and plasma cells;  
2. Early granulomatous formation described as circumscribed epithelioid granulomas 
with reticulin fibers but with no dense collagen layer surrounding them;  
3. Mature and healed granuloma with collagen in their periphery;  
4. Mixed pattern (early and mature granuloma in the same pulmonary area);  
5. Pulmonary fibrosis.  
In addition, the pulmonary lesions could be either diffuse or circumscribed (Machado, 
1965).  
Most recently, a study that included 23 patients with lung samples obtained by surgical 
biopsy or at necropsy showed similar pathological features that included alveolar wall and 
interlobular septal thickening, as determined by the accumulation of inflammatory cells or, 
less frequently, by fibrosis; filling of the alveolar spaces with inflammatory exudate; 
granulomas with or without fibrosis; and other evidence of fibrosis, such as architectural 
distortion and honeycombing. Cavitation secondary to necrosis was also a common finding 
(Marchiori et al., 2011).  
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As mentioned before, the PCM experimental animal models revealed a chronic, progressive 
infection that closely resembled human lesions but that did not reproduce certain 
histopathological aspects such as cavitated nodules, emphysema and the honeycombing 
pattern. 
5. Radiological aspects of PCM in humans and experimental mice 
Conventional HRCT has been applied as a noninvasive tool to evaluate and quantify 
pulmonary damage occurring in our experimental model of PCM (Lopera et al., 2010). This 
work has revealed that noninvasive conventional medical x-ray tomography is adequate to 
follow the sequential lung lesions in experimental PCM in mice. This procedure allowed 
detection of the main pathological patterns, the differential topographic distribution of the 
pulmonary lesions in both lungs, and their intensity.  
The intensity of the inflammatory reaction, evaluated by histomorphometry, increased until the 
12th week of infection, with a subsequent decrease due to the tendency to form predominantly 
compact and more isolated pseudotumoral masses. This histopathological behavior was also 
detected by HRCT, as expressed by lung density measures (Hounsfield units, HU) that showed 
a significant correlation, mainly in the upper or hilar lung region (Figure 5).  
When the mice were followed up sequentially, HRCT showed that 80% of them had 
peribronchial consolidations that persisted throughout the evaluation periods. Pulmonary 
consolidations were associated with a significant increase in upper lung density as 
compared with controls, −263±29 vs. −426±8 HU at week 4 (p<0.001), −191±25 vs. −403±17 
HU at week 8 (p<0.001), and −269±43 vs. −445±12 at week 12 (p<0.001). At week 16, upper 
consolidations tended to decrease as well as the corresponding density, −356±33 vs. −466±9 
(p<0.01).  
Histopathological analysis revealed that consolidation, as assessed by HRCT, was 
equivalent histologically to a confluent granulomatous reaction, while nodules 
corresponded to individual compact granulomas. During the same period of infection, 
confluent granulomas formed pseudotumoral masses that obstructed large bronchi. Discrete 
focal fibrosis was visible gradually around granulomas, but this finding was only evident 
with histopathology. 
Comparing the above results with radiological findings in patients is difficult because the 
size of lungs, the resolution of the topographer and the protocols used.  
In humans, assessment of disease progression and treatment outcome normally includes 
chest x-rays and then CT studies. At the time of diagnosis and in patients with active 
disease, chest x-ray revealed interstitial and alveolar-interstitial infiltrates, often bilateral 
and symmetrical, occasionally confluent, located preferentially in the central and basal areas 
of the lung (pattern in butterfly wings) (do Valle et al., 1992; Trad et al., 2006). A study of 
radiological monitoring carried out in 173 patients with chronic PCM reported presence of 
reticular interstitial infiltrates in 89.3% of the cases and nodular in 54.5%, bilateral alveolar 
in 45.4%, and mixed (in butterfly wings) in 44.7%. Emphysema was reported in 34.1%, septal 
lines by 25.7%, pleural thickening by 7.5%. Nine cases (6.8%) presented cavitations and three 
cases (2.2%) giant nodules or masses (Trad et al., 2006).  
CT proved superior to conventional radiographs in demonstrating early interstitial reticular 
and nodular infiltrates and showed abnormal findings in the majority of patients with 
chronic pulmonary PCM (more than 93%).  
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Fig. 5. Patterns of the main lung lesion as detected by conventional medical HRCT and 
histopathological methods in the experimental mouse PCM model.  A, C, E correspond to 
HRCT images and B, D, F show the corresponding histopathological lesions taken in a 
coronal plane. The upper right symbol in (A) indicates posterior or dorsal (P), anterior or 
ventral (A), left (L) and right (R) regions.  Dotted lines in B, D and F show an approximated 
position of the tomographic section. (A) Large nodular lesion represented by a peri-
bronquial consolidation (arrow) is located at right hilar region and other left small nodules 
are indicated by arrowhead. (B) Several nodules with varied sizes. (C) Confluent lesion 
expressed by left central peri-bronchial consolidation (arrow) extended from the hilum to 
large area of the parenchyma. (D) Consolidated areas of perivascular and justabronchial 
granulomatous lesions. (E) Pseudotumoral lesion defining a left central pulmonary mass 
(arrow). (F) Left central pseudotumoral mass obstructing the bronchus. Scale bar for HRCT 
images = 1 cm. Scale bar for histopathological images = 2 mm. Adapted from PLoS Negl 
Trop Dis 4(6): e726. doi:10.1371/journal.pntd.0000726.g005. 
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The most frequent HRCT findings in patients with pulmonary PCM were ground-glass 
attenuation areas; small centrilobular, cavitated and large nodules; parenchymal bands; 
airspace consolidations; interlobular septal thickening; architectural distortion; traction 
bronchiectasis; paracicatricial emphysema and fibrosis. Most of those HRCT findings 
concentrated in the periphery and posterior regions involving all lung zones, with slight 
increased intensity in the middle zones (Funari et al., 1999; Marchiori et al., 2008, 2009; 
Muniz et al., 2002; Souza et al., 2006). The radiologic patterns described above in patients 
with pulmonary PCM were dependent on the stage of the disease and on the exclusion or 
inclusion of patients who had received previous treatment were excluded. 
 
 
Fig. 6. Radiological findings in a patient with chronic pulmonary PMC at diagnosis.  
(A, B) Postero-anterior chest and lateral radiographs showing bilateral reticulonodular and 
ground-glass opacities with cavitations. (C) HRCT shows consolidations, ground glass 
attenuations and cavitated masses.  
6. Final remarks 
Infection by P. brasiliensis is, no doubt, acquired only in the endemic areas of Central and 
South America, especially in Brazil. However, as the fungus exhibits the capacity to remain 
dormant in the tissues of the infected human host for extended periods and is, likewise, able 
to regain its vitality giving rise to overt disease, one may encounter the mycosis in 
individuals living in non-autochthonous areas, distant from those where the primary 
infection was acquired. 
This is why it is imperative to keep informed physicians and other health-related 
professionals on this endemic mycosis and be prepared to include it among the differential 
diagnoses of disorders compatible with PCM. A detailed interrogation on the patient’s 
former places of residence or visit should be obtained in order to focus the diagnosis. On the 
same token, P. brasiliensis should be taken into considerations whenever clinical samples and 
biopsies are being analyzed. It is only through knowledge that the specific diagnosis will be 
made in these difficult to diagnose non-autochthonous cases.  
One of the main aims of this chapter was educational, namely, informing pneumologists 
and related professionals of the existence of this “tropical” disorder. It should be 
remembered that P. brasiliensis travels along with its host to any part of the world and that 
this host, now ill, may well be your own patient. 
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